Skip to content
Home
About Us
Meet Invitrocue
Our Team
Partners
Corporate Governance
Careers
Oncology
Onco-PDO™
Patient FAQ
Physician FAQ
Preclinical Services
Overview
Drug Metabolism and Pharmacokinetics
Toxicology and Safety Assessment
Hepatocytes
3D Cell Culture
Customized Assays and Disease Modelling
Invivocue’s HiMice
Shareholders
Reports
Financial Reports
Analyst Reports
Announcements
Contact Management
News & Resources
Publications
Conferences & Events
Press Releases
Privacy Policy
Contact Us
English
English
Deutsch
Español
Português
中文 (中国)
中文 (香港)
Menu
Home
About Us
Meet Invitrocue
Our Team
Partners
Corporate Governance
Careers
Oncology
Onco-PDO™
Patient FAQ
Physician FAQ
Preclinical Services
Overview
Drug Metabolism and Pharmacokinetics
Toxicology and Safety Assessment
Hepatocytes
3D Cell Culture
Customized Assays and Disease Modelling
Invivocue’s HiMice
Shareholders
Reports
Financial Reports
Analyst Reports
Announcements
Contact Management
News & Resources
Publications
Conferences & Events
Press Releases
Privacy Policy
Contact Us
English
English
Deutsch
Español
Português
中文 (中国)
中文 (香港)
Shareholders
Financial Reports
Delisting from ASX Official List
February 26, 2021
Read More >>
Appendix 4C – quarterly
February 1, 2021
Read More >>
VIEW ALL
Analyst Reports
Biotech Daily May 2019 – Dr Boreham's Crucible
June 13, 2019
Read More »
Gordon Capital – October 2019 Research Updates
February 13, 2019
Read More »
VIEW ALL
Announcements
Operational Updates and Management Accounts
February 18, 2022
Read More >>
Quarterly Updates – March 2021
May 3, 2021
Read More >>
VIEW ALL
Are you interested in Invitrocue?
Get in touch with our team.
All enquiries are welcome. We look forward to hearing from you!
CONTACT US